Management and outcomes of patients hospitalized with severe COVID-19 at a tertiary care center in midwestern United States
Knowledge of treatment regimens and outcomes for novel coronavirus disease 2019 (COVID-19) is evolving. Recent studies have reported mortality rates ranging from 39-50% among hospitalized patients with COVID-19. We report our experience ofmanagement and outcomes of hospitalized patients with COVID-19 at a large tertiary-care center in Midwestern United States. Of 658 patients presenting to our tertiary care center, 217 needed hospitalization, majority (77%) of whom were severely sick requiring admission to the intensive care unit (ICU). All received corticosteroids, and 78% of the patients received tocilizumab. More than two-thirds of the patients received anticoagulation and 80% of patients in the ICU had prone-positioning. The median duration of hospitalization was 12 days (interquartile range, 8 to16), median duration of intensive care unit stay was 7 days (interquartile range, 5 to 9) and requirement of mechanical ventilation was 6 days (interquartile range, 5 to 8) in our cohort. Of the 217 patients, 27 died (12% mortality). The majority of our patients received corticosteroids, tocilizumab, anticoagulation and prone positioning. While higher mortality rates of >30% have been reported in various studies among hospitalized patients with COVID-19, the majority of hospitalized patients in our cohort survived with a low mortality rate. The majority of our patients received corticosteroids, tocilizumab, anticoagulation and prone positioning. While higher mortality rates of >30% have been reported in various studies among hospitalized patients with COVID-19, the majority of hospitalized patients in our cohort survived with a low mortality rate.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:90 |
---|---|
Enthalten in: |
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace - 90(2020), 4 vom: 08. Okt. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gupta, Sandeep [VerfasserIn] |
---|
Links: |
---|
Themen: |
3QKI37EEHE |
---|
Anmerkungen: |
Date Completed 23.10.2020 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.4081/monaldi.2020.1592 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM316289493 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM316289493 | ||
003 | DE-627 | ||
005 | 20231225160749.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.4081/monaldi.2020.1592 |2 doi | |
028 | 5 | 2 | |a pubmed24n1054.xml |
035 | |a (DE-627)NLM316289493 | ||
035 | |a (NLM)33059413 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Gupta, Sandeep |e verfasserin |4 aut | |
245 | 1 | 0 | |a Management and outcomes of patients hospitalized with severe COVID-19 at a tertiary care center in midwestern United States |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 23.10.2020 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Knowledge of treatment regimens and outcomes for novel coronavirus disease 2019 (COVID-19) is evolving. Recent studies have reported mortality rates ranging from 39-50% among hospitalized patients with COVID-19. We report our experience ofmanagement and outcomes of hospitalized patients with COVID-19 at a large tertiary-care center in Midwestern United States. Of 658 patients presenting to our tertiary care center, 217 needed hospitalization, majority (77%) of whom were severely sick requiring admission to the intensive care unit (ICU). All received corticosteroids, and 78% of the patients received tocilizumab. More than two-thirds of the patients received anticoagulation and 80% of patients in the ICU had prone-positioning. The median duration of hospitalization was 12 days (interquartile range, 8 to16), median duration of intensive care unit stay was 7 days (interquartile range, 5 to 9) and requirement of mechanical ventilation was 6 days (interquartile range, 5 to 8) in our cohort. Of the 217 patients, 27 died (12% mortality). The majority of our patients received corticosteroids, tocilizumab, anticoagulation and prone positioning. While higher mortality rates of >30% have been reported in various studies among hospitalized patients with COVID-19, the majority of hospitalized patients in our cohort survived with a low mortality rate. The majority of our patients received corticosteroids, tocilizumab, anticoagulation and prone positioning. While higher mortality rates of >30% have been reported in various studies among hospitalized patients with COVID-19, the majority of hospitalized patients in our cohort survived with a low mortality rate | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
650 | 7 | |a Anticoagulants |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Glucocorticoids |2 NLM | |
650 | 7 | |a remdesivir |2 NLM | |
650 | 7 | |a 3QKI37EEHE |2 NLM | |
650 | 7 | |a Adenosine Monophosphate |2 NLM | |
650 | 7 | |a 415SHH325A |2 NLM | |
650 | 7 | |a tocilizumab |2 NLM | |
650 | 7 | |a I031V2H011 |2 NLM | |
650 | 7 | |a Alanine |2 NLM | |
650 | 7 | |a OF5P57N2ZX |2 NLM | |
700 | 1 | |a Kaushik, Ashlesha |e verfasserin |4 aut | |
700 | 1 | |a Gupta, Jitendra |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace |d 1994 |g 90(2020), 4 vom: 08. Okt. |w (DE-627)NLM074863649 |x 1122-0643 |7 nnns |
773 | 1 | 8 | |g volume:90 |g year:2020 |g number:4 |g day:08 |g month:10 |
856 | 4 | 0 | |u http://dx.doi.org/10.4081/monaldi.2020.1592 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 90 |j 2020 |e 4 |b 08 |c 10 |